REHOVOT, Israel, and BRIDGEWATER, N.J., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Foamix Pharmaceuticals Ltd. (Nasdaq:FOMX), ("Foamix Pharmaceuticals"), a clinical stage specialty pharmaceutical company focused on developing and commercializing proprietary topical foams to address unmet needs in dermatology, today announced that it will host a Key Opinion Leader breakfast on Tuesday, November 4, 2014 from 8:00am-9:30am Eastern Time in New York City.
The meeting will feature key opinion leader Mark Lebwohl, MD, who leads a renowned dermatology program in the U.S., as the Sol and Clara Kest Professor and Chairman of Mount Sinai's Department of Dermatology, a position that he has held since 1996. Dr. Lebwohl has been elected President of the American Academy of Dermatology for the 2015-16 term. Dr. Lebwohl's main areas of clinical interest include psoriasis and skin cancer. Notably, he identified one of the first topical therapies approved for skin cancer and for pre-cancerous lesions. He has also authored or co-authored more than 500 publications and written and edited several books, including the first atlas devoted entirely to cutaneous manifestations of systemic disease, and the leading book on dermatologic therapy, Treatment of Skin Disease.
Key members of the Foamix executive management team, including Dov Tamarkin, Chief Executive Officer, and Dave Domzalski, President of U.S. Subsidiary Foamix Pharmaceuticals Inc., will provide a brief overview of the company and will also be available for Q&A.
The event is intended for institutional investors and sell-side analysts only. To reserve a place, please contact Veronica Molina at 212-915-2567 or via e-mail at email@example.com. A live webcast and subsequent replay of the event will be available at http://lifesci.rampard.com/20141104/, and will also be accessible through the Investors section of the Company's website at http://foamixpharma.com.
About Foamix Pharmaceuticals Ltd.
Foamix Pharmaceuticals is a clinical-stage specialty pharmaceutical company focused on developing and commercializing its proprietary minocycline foam for the treatment of acne, impetigo and other skin conditions. Foamix Pharmaceuticals' lead product candidates, FMX101 for moderate-to-severe acne and FMX102 for impetigo, are novel topical foam formulations of the antibiotic minocycline. Foamix Pharmaceuticals also has early-stage stable foam formulations of various drugs for the treatment of common dermatological indications.
Cautionary Note Regarding Forward-Looking Statements
This press release may contain "forward-looking statements" relating to future events. Forward-looking statements are based on Foamix Pharmaceuticals' current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions. Actual results and the timing of events could differ materially from those anticipated in these forward-looking statements as a result of several factors. Any forward-looking statements that may be made herein speak only as of the date of this release and Foamix Pharmaceuticals undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law.
CONTACT: Dov Tamarkin, CEO Foamix Pharmaceuticals Ltd. +972-8-9316233 firstname.lastname@example.org U.S. Investor Relations Michael Rice LifeSci Advisors, LLC 646-597-6979 email@example.comSource:Foamix, Ltd.